China Biosimilar Monoclonal Antibody Market (2025-2031) | Analysis, Share, Companies, Forecast, Growth, Outlook, Size & Revenue, Trends, Industry, Value, Competitive Landscape, Segmentation

2.1 Key Highlights of the Report

2.2 Report Description

2.3 Market Scope & Segmentation

2.4 Research Methodology

2.5 Assumptions

3.1 China Country Macro Economic Indicators

3.2 China Biosimilar Monoclonal Antibody Market Revenues & Volume, 2021 & 2031F

3.3 China Biosimilar Monoclonal Antibody Market - Industry Life Cycle

3.4 China Biosimilar Monoclonal Antibody Market - Porter's Five Forces

3.5 China Biosimilar Monoclonal Antibody Market Revenues & Volume Share, By Type, 2021 & 2031F

3.6 China Biosimilar Monoclonal Antibody Market Revenues & Volume Share, By Indication, 2021 & 2031F

3.7 China Biosimilar Monoclonal Antibody Market Revenues & Volume Share, By End User, 2021 & 2031F

4.1 Impact Analysis

4.2 Market Drivers

4.2.1 Increasing prevalence of chronic diseases in China

4.2.2 Growing demand for affordable biologic drugs

4.2.3 Supportive government policies promoting biosimilar adoption

4.3 Market Restraints

4.3.1 Intellectual property rights protection concerns

4.3.2 Regulatory challenges in biosimilar approval process

4.3.3 Limited awareness and acceptance of biosimilars among healthcare professionals and patients

6.1 China Biosimilar Monoclonal Antibody Market, By Type

6.1.1 Overview and Analysis

6.1.2 China Biosimilar Monoclonal Antibody Market Revenues & Volume, By Type, 2021- 2031F

6.1.3 China Biosimilar Monoclonal Antibody Market Revenues & Volume, By Adalimumab, 2021- 2031F

6.1.4 China Biosimilar Monoclonal Antibody Market Revenues & Volume, By Bevacizumab, 2021- 2031F

6.1.5 China Biosimilar Monoclonal Antibody Market Revenues & Volume, By Infliximab, 2021- 2031F

6.1.6 China Biosimilar Monoclonal Antibody Market Revenues & Volume, By Rituximab, 2021- 2031F

6.1.7 China Biosimilar Monoclonal Antibody Market Revenues & Volume, By Trastuzumab, 2021- 2031F

6.1.8 China Biosimilar Monoclonal Antibody Market Revenues & Volume, By Others, 2021- 2031F

6.2 China Biosimilar Monoclonal Antibody Market, By Indication

6.2.1 Overview and Analysis

6.2.2 China Biosimilar Monoclonal Antibody Market Revenues & Volume, By Oncology, 2021- 2031F

6.2.3 China Biosimilar Monoclonal Antibody Market Revenues & Volume, By Autoimmune diseases, 2021- 2031F

6.2.4 China Biosimilar Monoclonal Antibody Market Revenues & Volume, By Others, 2021- 2031F

6.3 China Biosimilar Monoclonal Antibody Market, By End User

6.3.1 Overview and Analysis

6.3.2 China Biosimilar Monoclonal Antibody Market Revenues & Volume, By Hospitals, 2021- 2031F

6.3.3 China Biosimilar Monoclonal Antibody Market Revenues & Volume, By Cancer treatment centers, 2021- 2031F

6.3.4 China Biosimilar Monoclonal Antibody Market Revenues & Volume, By Others, 2021- 2031F

7.1 China Biosimilar Monoclonal Antibody Market Export to Major Countries

7.2 China Biosimilar Monoclonal Antibody Market Imports from Major Countries

8.1 Number of approved biosimilar monoclonal antibodies in China

8.2 Investment in biosimilar research and development in China

8.3 Adoption rate of biosimilar monoclonal antibodies by healthcare institutions

8.4 Number of clinical trials for biosimilar monoclonal antibodies in China

8.5 Patient and physician education initiatives on biosimilars

9.1 China Biosimilar Monoclonal Antibody Market Opportunity Assessment, By Type, 2021 & 2031F

9.2 China Biosimilar Monoclonal Antibody Market Opportunity Assessment, By Indication, 2021 & 2031F

9.3 China Biosimilar Monoclonal Antibody Market Opportunity Assessment, By End User, 2021 & 2031F

10.1 China Biosimilar Monoclonal Antibody Market Revenue Share, By Companies, 2024

10.2 China Biosimilar Monoclonal Antibody Market Competitive Benchmarking, By Operating and Technical Parameters